Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals

Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide found a very high likelihood of study success, the company announced Tuesday.